Also known as: UMBC
BriaCell Therapeutics announced an asset purchase agreement transferring its Soluble CD80 license to majority-owned subsidiary BriaPro, while four abstracts were accepted for presentation at the 2026 AACR Annual Meeting.
BriaCell Therapeutics transfers exclusive license for Soluble CD80 cancer therapy to subsidiary BriaPro in deal valued at C$1.18 million, with BriaCell retaining 78% stake and providing $3 million credit facility.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07782268 |
Written Exposure in Substance Treatment (WEST 3.0): Randomized Controlled Trial |
NOT_YET_RECRUITING | NA |
| NCT07684703 |
Consensus And Norms for Medical Visualization Academic Standards Study - A Modified Delphi Study |
NOT_YET_RECRUITING | |
| NCT07282821 |
Bempedoic Acid Therapy for Polycystic Kidney Disease |
NOT_YET_RECRUITING | PHASE2 |
| NCT07172776 |
A Community Engagement Approach to Improving Communication With Black Men About Oral and Pharyngeal Cancers |
NOT_YET_RECRUITING | NA |
| NCT07108608 |
Adaptation of Written Exposure Therapy in Substance Treatment |
COMPLETED | NA |
| NCT06913049 |
The Development, Implementation, and Evaluation of a Social Engagement Support System |
NOT_YET_RECRUITING | NA |
| NCT06296940 |
Written Exposure in Substance Treatment |
COMPLETED | NA |
| NCT05694637 |
Botswana Smoking and Abstinence Reinforcement Trial |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT05558332 |
Youth Nominated Support Team |
ACTIVE_NOT_RECRUITING | NA |
| NCT04201600 |
Glucose Variability and Cognition in Prediabetes |
RECRUITING |
